Every engagement at Vanta Bioscience begins with a scientific conversation, not a sales process. When a sponsor reaches out—whether at the earliest stages of compound characterization or ahead of a regulatory submission—our first step is to understand the study objectives, the regulatory context, and the constraints around timeline and budget. This initial alignment allows us to assess feasibility accurately and identify any design considerations before a formal proposal is developed. Sponsors working with limited internal infrastructure often benefit from this early input, as it surfaces questions that would otherwise slow execution later.
Proposal development at Vanta reflects a mutual understanding of what the study must accomplish. We do not issue templated quotes; each proposal is built around the specific scientific and regulatory needs of the program. This includes identifying the appropriate test system, defining endpoints that will satisfy the intended regulatory pathway, and flagging any areas where study design may require flexibility. Our goal at this stage is to ensure that both teams—sponsor and CRO—are operating from the same understanding before study initiation.
Once a proposal is accepted, Vanta’s scientific and project management teams work with the sponsor to finalize the protocol with precision. Sponsors are encouraged to share as much program context as possible at this stage, including prior study data, target indications, and submission timelines. This two-way exchange is not a formality—it directly affects how the study is designed, how results are interpreted, and how quickly a final report can be delivered in a format useful for regulatory review.
Project Execution
Study execution at Vanta is managed against a defined project plan that includes protocol finalization, study initiation, in-life phase milestones, sample analysis, and report delivery. Each study is assigned a dedicated project manager who serves as the primary point of coordination between the sponsor and Vanta’s internal teams—including study directors, pathologists, laboratory staff, and QA personnel. This structure ensures accountability at each phase and reduces the communication gaps that frequently cause delays in multi-functional preclinical programs.
A core principle of our execution model is that adaptability is built in, not treated as an exception. Preclinical studies frequently encounter situations requiring protocol amendments, dose adjustments, or changes in sampling strategy based on interim findings. Vanta’s teams are structured to manage these situations with scientific rigor and without disruption to the broader timeline. When unexpected results arise, the study director and project manager engage the sponsor promptly, presenting options with a clear assessment of regulatory and operational impact.
Data integrity and traceability are non-negotiable at every stage of execution. All raw data is generated and maintained in accordance with GLP principles, with full audit trails and documented chain of custody for samples and records. Final reports are structured to meet the expectations of regulatory agencies in the US, EU, and other applicable jurisdictions, reducing the need for supplementary submissions or data clarifications after delivery.
Communication & Transparency
Sponsors working with external CROs frequently cite fragmented communication and delayed access to study data as primary sources of operational friction. Vanta addresses this directly through structured communication protocols: sponsors receive regular study updates at defined intervals, milestone notifications when key study events occur, and immediate escalation when issues require sponsor input or decision-making. Reporting formats are standardized and consistent across studies, so sponsors managing multiple programs are not reconciling different documentation styles from different teams.
All study documentation—including protocols, amendments, deviation reports, and draft reports—is made accessible to sponsors in an organized and timely manner. Scientific queries are directed to the study director or senior scientific staff, not filtered through administrative layers. Sponsors working across multiple time zones are accommodated through scheduled calls and written summaries that maintain continuity without requiring real-time availability at every touchpoint.
Engagement Models
Vanta supports multiple engagement structures to reflect the operational realities of sponsors at different stages of development. Full-service engagements cover the complete scope of a study program—from study design and protocol development through execution, analysis, and final reporting. Standalone study engagements are structured for sponsors who require a specific test to complement work conducted in-house or at another facility.
Early-stage companies without dedicated regulatory or preclinical staff often rely more heavily on Vanta’s scientific team for input on study design, regulatory strategy, and data interpretation. Established organizations with internal teams typically require a more defined execution partnership, with Vanta functioning as an operational extension of their preclinical group. Both models are supported equally within our project management structure, and the level of sponsor involvement at each phase is defined at the outset to ensure alignment throughout the program.
Client Resources
Sponsors working with Vanta have access to scientific and regulatory support resources designed to inform decision-making at each stage of program development. This includes guidance on study design for specific regulatory pathways—such as ICH, OECD, EPA, and OPPTS guidelines—as well as input on how study outcomes may be positioned within a broader submission strategy.
This support is particularly relevant for sponsors navigating a regulatory pathway for the first time, or expanding into a new jurisdiction where local requirements differ from prior experience.
Documentation resources are made available in a structured format throughout the study lifecycle. Protocols are drafted in accordance with the applicable guideline and submitted for sponsor review prior to finalization. Study reports follow standard regulatory formats and include all raw data appendices, statistical summaries, and pathology or analytical findings as required. For sponsors building integrated data packages, Vanta can provide guidance on cross-study formatting consistency to reduce the burden of submission preparation.
Vanta also maintains a repository of technical resources—including regulatory summaries, test guideline overviews, and case-based insights from studies conducted across therapeutic and chemical categories. These materials are intended to support scientific and regulatory teams in evaluating study options, interpreting guideline requirements, and understanding how specific endpoints are typically assessed in regulatory review. Access to these resources is available to sponsors upon engagement and can be discussed in the context of an active or planned program.
Have Questions? Get in Touch
Can’t find the specific resource, code template, or compliance documentation you need?
Our team of professional architects is ready to assist you.